Nuvalent (NUVL) CFO sells 11,430 shares after option exercise under 10b5-1 plan
Nuvalent's CFO, Alexandra Balcom, exercised stock options for 11,430 shares at $1.08 per share and subsequently sold all those shares in open-market transactions at weighted average prices between $103.81 and $106.69. These transactions were pre-arranged under a Rule 10b5-1 trading plan adopted on December 23, 2025, indicating a routine liquidity management strategy rather than a change in insider sentiment. Following these sales, Balcom directly holds 85,533 shares of Nuvalent Class A common stock.
[Form 4] Nuvalent, Inc. Insider Trading Activity
A recent Form 4 filing reveals insider trading activity at Nuvalent, Inc. (NUVL), with officer Benjamin Lane receiving new equity-based compensation. On April 1, 2026, Lane was granted a stock option for 19,000 shares and 9,500 restricted stock units (RSUs). After these transactions, Lane directly holds 50,368 shares of Class A common stock and 19,000 stock options.
Nuvalent (NUVL) CDO exercises options, sells 5,500 shares under 10b5-1 plan
Nuvalent's Chief Development Officer, Darlene Noci, exercised options to acquire 5,500 shares of Class A Common Stock at $27.85 per share and subsequently sold those 5,500 shares in two open-market trades at weighted average prices of $97.43 and $98.13. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 18, 2024. Following these sales, Noci retains a substantial equity stake, directly holding 58,117 shares and 97,829 option shares.
22,000 Class A shares proposed sale — NUVL (NASDAQ: NUVL)
Nuvalent, Inc. (NASDAQ: NUVL) has filed a Form 144 to announce the proposed sale of 22,000 Class A Common shares on March 30, 2026, as a result of a stock option exercise. The filing also details prior open-market disposals by Darlene Noci of 4,000 shares on December 30, 2025, 5,500 shares on January 29, 2026, and another 5,500 shares on February 26, 2026. These transactions involve restricted or insider-held shares being sold to the public under Rule 144.
Nuvalent (NUVL) CLO exercises 5.5K options, sells 5.5K shares under 10b5-1
Nuvalent's Chief Legal Officer, Deborah Ann Miller, executed a pre-arranged transaction, exercising options for 5,500 shares at $6.89 each and subsequently selling those 5,500 shares in the open market for weighted average prices between $97.50 and $99.46. These transactions were conducted under a Rule 10b5-1 trading plan established in November 2024. After the sales, Miller directly holds 59,634 shares and retains 83,608 stock options.
Nuvalent (NUVL) CFO sells 25,130 shares in Rule 10b5-1 trades
Nuvalent, Inc. (NUVL) CFO Alexandra Balcom reported exercising stock options for 11,430 shares and subsequently selling a total of 25,130 Class A Common Stock shares in open-market transactions on March 24 and 25, 2026. These sales, conducted under a Rule 10b5-1 trading plan established on December 23, 2025, resulted in her directly holding 85,533 shares of Nuvalent Class A Common Stock after these transactions. Weighted-average prices for the sales ranged from the mid-$90s to $100.16 per share.
NUVL (NASDAQ: NUVL) files Form 144 to sell Class A shares via J.P. Morgan
Nuvalent, Inc. (NASDAQ: NUVL) has filed a Form 144 indicating proposed sales of Class A Common shares through J.P. Morgan Securities LLC. The filing details multiple lots of shares, including 30,019, 15,701, 4,728, and 8,972 shares, tied to option exercises and cash transactions with dates of 03/24/2026 and 12/17/2024. This is a notice of proposed insider sales, not a confirmation of completed transactions.
Nuvalent (NUVL) officer Benjamin Lane details stock, options and RSUs in Form 3
Nuvalent, Inc. officer Benjamin Lane has filed a Form 3, an initial statement of beneficial ownership, detailing his equity holdings in the company. The filing indicates he directly holds 40,868 shares of Class A Common Stock, along with various stock options and restricted stock units (RSUs) that will convert to additional shares upon vesting. This report outlines his baseline ownership and compensation structure, rather than any recent trading activity.
Nuvalent's Chief Scientific Officer Sells Over 35,000 Shares
Nuvalent's Chief Scientific Officer, Henry E. Pelish, sold 35,104 shares of Class A Common Stock in multiple transactions on March 12 and 13, 2026. The sales totaled $3,442,856, with prices ranging from $97.79 to $99.71 per share. Pelish now directly owns 65,604 shares of Nuvalent's Class A Common Stock.
Vestal Point Sells Nuvalent Shares: Portfolio Impact and Company Outlook - News and Statistics
Vestal Point Capital significantly reduced its stake in Nuvalent Inc. by selling over one million shares in mid-February, as disclosed in a regulatory filing. This transaction, valued based on quarterly average pricing, substantially decreased Nuvalent's presence in Vestal Point's portfolio. Despite the sale, Nuvalent's stock notably increased over the past year, and the clinical-stage biotechnology company, focused on cancer therapies, maintains a strong financial position with anticipated regulatory events for its lead drug candidates later this year.
Nuvalent (NUVL) CSO sells 35,104 shares after major option exercises
Nuvalent, Inc.'s Chief Scientific Officer, Henry E. Pelish, exercised stock options for 17,320 shares and subsequently sold 35,104 shares of Class A Common Stock in mid-March 2026. These transactions, executed under a pre-arranged Rule 10b5-1 trading plan, involved sales at weighted average prices around the high-$90s. Following these trades, Pelish directly holds 65,604 shares of Nuvalent Class A Common Stock.
[144] Nuvalent, Inc. SEC Filing
This article details Nuvalent, Inc.'s SEC Form 144 filing, a notice of proposed sale of securities under Rule 144. The filing indicates a proposed sale of 90,000 shares of Class A Common Stock with an aggregate market value of $8,816,400. The shares were acquired through a stock option exercise on March 6, 2026, and are intended to be sold on the Nasdaq exchange.
Nuvalent (NASDAQ: NUVL) CEO sells 30K shares after option exercise
Nuvalent, Inc. President and CEO James Richard Porter exercised options for 30,000 shares of Class A common stock at $27.85 per share. On the same day, he sold these 30,000 shares in open-market transactions at weighted average prices around $98.59, $99.29, and $100.19. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan, and following the sales, Porter directly holds 324,879 shares of Nuvalent.
NUVL - Nuvalent, Inc. Latest Stock News & Market Updates
This page provides the latest news and updates for Nuvalent, Inc. (NUVL), a clinical-stage biopharmaceutical company focused on developing targeted kinase inhibitors for oncogene-driven cancers, particularly non-small cell lung cancer. It aggregates company announcements, press releases, and related coverage, detailing advancements in its lead investigational programs like zidesamtinib and neladalkib, clinical trial updates, regulatory milestones, and corporate developments. The historical news feed includes financial results and details of its initial public offering.
Nuvalent (NUVL) CDO exercises options and sells 5,500 shares under 10b5-1 plan
Nuvalent, Inc.'s Chief Development Officer, Darlene Noci, exercised stock options for 5,500 shares and subsequently sold all 5,500 shares of Class A common stock in open-market transactions on February 26, 2026. These sales, conducted under a Rule 10b5-1 trading plan adopted in November 2024, occurred at weighted average prices between $102.04 and $104.41 per share. After these transactions, Noci directly holds 58,117 Class A common shares.
Nuvalent (NUVL) CLO sells 5,500 shares after option exercise
Nuvalent, Inc.'s Chief Legal Officer, Deborah Ann Miller, exercised stock options for 5,500 shares of Class A common stock on February 26, 2026, at an exercise price of approximately $6.89 per share. On the same day, she sold all 5,500 shares in open-market transactions, ranging from $101.96 to $103.95 per share, under a Rule 10b5-1 trading plan. Following these transactions, Miller directly holds 59,634 shares of Class A common stock and 89,108 derivative securities.
NUVL SEC Filings - Nuvalent, Inc. 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Nuvalent (NUVL) SEC filings, including annual 10-K reports, quarterly 10-Q earnings, 8-K material events, and insider trading forms. Recent filings highlight key clinical trial data, NDA milestones for neladalkib and zidesamtinib, and details of capital market activities, including a public offering to fund operations into 2029. The platform also offers AI-powered summaries to help investors quickly parse complex legal and technical information found in these documents.
Nuvalent, Inc. SEC 10-K Report
Nuvalent, Inc. (NUVL) has released its annual Form 10-K report, detailing a net loss of $425.4 million for the year due to increased R&D and administrative expenses. The clinical-stage biopharmaceutical company is advancing two lead drug candidates, zidesamtinib and neladalkib, through clinical trials for NSCLC and plans to submit New Drug Applications for both in 2026. The company successfully raised significant capital through stock offerings and expects current funds to support operations until 2029, while acknowledging operational, regulatory, and financial risks.
Nuvalent, Inc. SEC Filing
This SEC filing details a proposed sale of 5,850 shares of Nuvalent, Inc. Class A common stock by an insider-related trust under Rule 144, with an aggregate market value of $588,990. The filing also discloses previous sales by the same trust in the preceding three months, highlighting insider activity for Nuvalent (NUVL).
Breakthrough Clinical Trial: Nuvalent's Cancer Drug Achieves 89% Response Rate, Fast-Track FDA Review Coming
Nuvalent's cancer drug, zidesamtinib, showed positive pivotal data in the ARROS-1 clinical trial for ROS1-positive NSCLC patients, achieving an 89% response rate in TKI-naïve patients and favorable results in TKI pre-treated individuals. The company plans to initiate a rolling New Drug Application (NDA) submission to the FDA in July 2025, with an agreement for Real-Time Oncology Review participation. This development offers renewed hope for a new, potential best-in-class treatment option for advanced ROS1-positive NSCLC.
Nuvalent to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
Nuvalent, Inc. announced its participation in the Guggenheim Emerging Outlook: Biotech Summit 2026. CEO James Porter and CFO Alexandra Balcom will hold a fireside chat on Thursday, February 12, 2026, at 1:30 p.m. ET in NYC. A live webcast and archive will be available on Nuvalent's investor website.
Nuvalent Announces OnTarget 2026 Operating Plan Progress and Outlines Key Anticipated 2026 Milestones
Nuvalent, Inc. announced significant progress on its "OnTarget 2026" operating plan, including the FDA's acceptance of an NDA for zidesamtinib for advanced ROS1-positive NSCLC with a PDUFA target date of September 18, 2026. The company also plans to submit an NDA for neladalkib in ALK-positive NSCLC in the first half of 2026 and expand the zidesamtinib indication in the second half. Nuvalent reported a strong cash position of approximately $1.4 billion, providing an operating runway into 2029, and will present at the 44th Annual J.P. Morgan Healthcare Conference.
This Insider Has Just Sold Shares In Nuvalent
Nuvalent's CEO, President & Director, James Porter, recently sold shares worth US$2.7m at an average price of US$97.26, reducing his total holding by 12%. While this was the largest insider sale in the past year, insiders have not bought any shares during the same period, despite owning a significant 2.5% of the company. This selling activity makes analysis cautious, although high insider ownership generally indicates alignment with shareholder interests.
Nuvalent (NUVL) chief legal officer Miller sells $676k in stock
Nuvalent's Chief Legal Officer, Deborah Ann Miller, sold 6,902 shares of Class A Common Stock for approximately $676,157 to cover tax obligations from vesting equity awards. Despite this sale, Miller acquired 17,500 shares and stock options for another 17,500 shares through RSUs, increasing her direct ownership to 59,634 shares. The company, while not yet profitable, showcases a strong financial position with more cash than debt and a high current ratio, alongside recent positive analyst ratings and a significant public offering to fund cancer therapy development.
Nuvalent (NUVL) chief development officer sells $721k in stock By Investing.com
Nuvalent's Chief Development Officer, Darlene Noci, sold 6,492 shares of Class A Common Stock for over $721,000, executed in multiple transactions across January 5th and 6th, 2026. Despite these sales, Noci acquired 17,500 shares and holds an option for an additional 17,500 shares, bringing her direct ownership to 58,117 shares. This comes amidst other significant company developments, including a $500 million public offering, a $315 million royalty deal with Royalty Pharma, and positive analyst ratings from UBS, Jefferies, and Truist Securities.
Nuvalent CSO Pelish sells shares worth $501,752
Nuvalent Inc.'s Chief Scientific Officer, Henry E. Pelish, sold 5,560 shares of Class A Common Stock for over $500,000 to cover tax obligations from vested equity awards. These sales were part of a pre-arranged trading plan, and Pelish also acquired additional shares and options. The company recently completed a $500 million public offering and a $315 million royalty deal, with analysts from UBS, Truist Securities, and Jefferies maintaining positive ratings.
Nuvalent (NUVL) chief development officer sells $721k in stock By Investing.com
Darlene Noci, Chief Development Officer of Nuvalent, Inc. (NASDAQ: NUVL), sold shares totaling $721,320 on January 5th and 6th, 2026. These sales were executed at varying prices per share in multiple transactions. Following these transactions, Noci acquired 17,500 shares and an option to purchase an additional 17,500 shares at an exercise price of $106.82, bringing her direct ownership to 58,117 shares.
Nuvalent (NUVL) chief legal officer Miller sells $676k in stock
Nuvalent's Chief Legal Officer, Deborah Ann Miller, sold 6,902 shares of Class A Common Stock for $676,157 to cover tax obligations. Despite the stock appearing overvalued according to InvestingPro's Fair Value assessment, the company recently acquired 17,500 shares and additional stock options valued at $0. This follows a significant public offering of $500 million and a $315 million royalty interest acquisition by Royalty Pharma, alongside positive analyst ratings for Nuvalent's cancer therapies.
Nuvalent (NUVL) chief legal officer Miller sells $676k in stock
Nuvalent's Chief Legal Officer, Deborah Ann Miller, sold 6,902 shares of Class A Common Stock for over $676,000 to cover tax obligations from vesting equity awards. Following these sales, Miller acquired 17,500 shares and stock options for another 17,500 shares through RSUs, which vest over several years. The company currently holds more cash than debt but is not yet profitable, with analysts expecting the next earnings report on March 4, 2026.
Nuvalent CSO Pelish sells shares worth $501,752 By Investing.com
Nuvalent Inc.'s Chief Scientific Officer, Henry E. Pelish, sold 5,560 shares of Class A Common Stock for over $501,752 to cover tax obligations. The sales were executed between January 5th and 6th, 2026, through a pre-arranged trading plan, with prices ranging from $96.06 to $98.52. Following these transactions, Pelish directly owns 65,888 shares of the company, and Nuvalent has also recently completed a significant public offering and royalty deal, alongside positive analyst ratings and a new board appointment.
Nuvalent (NUVL) chief development officer sells $721k in stock By Investing.com
Darlene Noci, Chief Development Officer of Nuvalent, Inc. (NASDAQ: NUVL), sold 6,492 shares of Class A Common Stock for a total of $721,320 in early January 2026. The sales occurred across multiple transactions with prices ranging from $96.06 to $98.52 per share. Following these transactions, Noci directly owns 58,117 shares, and also acquired 17,500 shares with a value of $0 and an option to purchase an equal number of shares at an exercise price of $106.82.
Nuvalent CSO Pelish sells shares worth $501,752 By Investing.com
Nuvalent Chief Scientific Officer Henry E. Pelish sold 5,560 shares of Class A Common Stock for over $500,000 to cover tax obligations, in accordance with a pre-arranged trading plan. Concurrently, Pelish acquired options and shares, increasing his direct ownership in the company. These transactions come amid positive company developments, including a successful public offering, a significant royalty deal, and favorable analyst ratings.
Nuvalent (NUVL) chief development officer sells $721k in stock By Investing.com
Darlene Noci, Chief Development Officer of Nuvalent, Inc. (NASDAQ: NUVL), sold 6,492 shares of Class A Common Stock for a total of $721,320 across January 5th and 6th, 2026. Despite these sales, Noci acquired 17,500 shares and an option to purchase another 17,500 shares on January 7th. Nuvalent has also recently closed a $500 million public offering, entered a $315 million royalty deal with Royalty Pharma, and received reiterated "Buy" ratings from UBS and Jefferies.
Nuvalent (NUVL) chief legal officer Miller sells $676k in stock
Nuvalent's Chief Legal Officer, Deborah Ann Miller, sold 6,902 shares of Class A Common Stock for over $676,000 to cover tax obligations from vesting equity awards. Concurrently, she acquired 17,500 shares and stock options for an additional 17,500 shares through RSUs, which will vest over several years subject to her continued service. Despite these transactions, Nuvalent is not yet profitable, though it holds more cash than debt and has recently completed a significant public offering and secured a royalty deal, attracting positive analyst coverage.
Nuvalent CSO Pelish sells shares worth $501,752 By Investing.com
Nuvalent's Chief Scientific Officer, Henry E. Pelish, sold 5,560 shares of Class A Common Stock for over $500,000 to cover tax obligations, while also acquiring additional shares and options. This news follows several significant developments for Nuvalent, including a successful public offering, a $315 million royalty deal, positive analyst ratings with increased price targets, and the appointment of Ron Squarer to its Board of Directors, reflecting strong progress in its biopharmaceutical ventures.
Nuvalent (NUVL) chief development officer sells $721k in stock
Nuvalent's Chief Development Officer, Darlene Noci, sold shares worth $721,320 in early January 2026, while also acquiring options for new shares. This comes amidst several significant developments for Nuvalent, including a successful $500 million public offering, a $315 million royalty deal with Royalty Pharma, and positive analyst ratings from UBS, Jefferies, and Truist Securities. The company also appointed Ron Squarer to its Board of Directors.
Nuvalent (NUVL) chief legal officer Miller sells $676k in stock
Nuvalent's Chief Legal Officer, Deborah Ann Miller, sold 6,902 shares of Class A Common Stock for $676,157 to cover tax obligations. Despite the sale, Miller acquired 17,500 shares through RSUs and stock options, increasing her direct ownership to 59,634 shares. The company, currently trading near its 52-week high, has recently completed a $500 million public offering and received positive analyst ratings for its cancer therapies.
Nuvalent (NUVL) chief development officer sells $721k in stock
Nuvalent's Chief Development Officer, Darlene Noci, sold 6,492 shares of Class A Common Stock for over $721,000 in early January 2026, with prices ranging from $96.06 to $98.52 per share. Following these sales, Noci acquired 17,500 shares and an option for another 17,500 shares, bringing her direct ownership to 58,117 shares. This comes amidst other significant company developments, including a $500 million public offering, a $315 million royalty deal with Royalty Pharma, and positive analyst ratings.
Nuvalent to Present at the 44th Annual J.P. Morgan Healthcare Conference
Nuvalent, Inc. announced that its Chief Executive Officer, James Porter, Ph.D., will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, at 9:00 a.m. PT. A live webcast of the presentation will be available on the company's website. Nuvalent is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer.
Royalty Pharma Acquires Royalty Interest in Nuvalent’s Neladalkib and Zidesamtinib for Up to $315 Million
Royalty Pharma plc has acquired a pre-existing royalty interest in Nuvalent's neladalkib and zidesamtinib for up to $315 million from an undisclosed third party. These next-generation tyrosine kinase inhibitors are in development for ALK and ROS1 mutation-positive non-small cell lung cancer, respectively. Neladalkib recently showed positive pivotal results, and zidesamtinib is currently under FDA review with an action date of September 18, 2026.
Nuvalent (NUVL) Valuation After FDA Breakthrough Designation and Investor Optimism in Lung Cancer Franchise
Nuvalent (NUVL) has gained investor attention following FDA Breakthrough Therapy Designation for its lung cancer drug, Zide, and strong share price performance. Despite current valuations suggesting the stock is overvalued by traditional metrics like Price to Book, analysts see potential for further upside. The company's future value hinges on the success of its oncology pipeline and commercialization efforts, particularly for Zide.
Nuvalent Appoints Ron Squarer to Board of Directors
Nuvalent, Inc. (Nasdaq: NUVL), a biopharmaceutical company, has appointed Ron Squarer to its Board of Directors, recognizing his extensive experience in oncology drug development and commercialization. Mr. Squarer's expertise is expected to significantly contribute to Nuvalent's pre-launch preparations for zidesamtinib, targeting ROS1-positive non-small cell lung cancer. This appointment aims to strengthen the company's capabilities as it works towards bringing novel kinase inhibitors to patients.
Nuvalent, Inc. (NUVL) is a Buy On lung Cancer Treatment Prospects
Nuvalent Inc. (NUVL) is highlighted as a compelling investment due to its promising lung cancer treatments, Nela and Zide. Both drugs are nearing commercialization, with Zide having secured Breakthrough Therapy Designation and expected regulatory approval soon. Analyst firms like Truist Securities and Jefferies have issued "Buy" ratings and raised price targets, citing strong clinical trial results and significant market potential for NUVL's innovative small-molecule therapies.
Nuvalent, Inc. (NUVL) is a Buy On lung Cancer Treatment Prospects
Nuvalent, Inc. (NUVL) is seen as a strong buy due to its promising lung cancer treatments, Nela and Zide. Truist Securities initiated coverage with a Buy rating and a $140 price target, highlighting the potential regulatory approval of Zide in early 2026. Additionally, Jefferies raised its price target to $164 after positive ALKove-1 trial results for neladalkib, positioning Nuvalent as a significant player in the ALK-positive lung cancer market.
Nuvalent, Inc. (NUVL) is a Buy On lung Cancer Treatment Prospects
Nuvalent Inc. (NUVL) is considered a strong buy due to its promising lung cancer treatments, Nela and Zide, which are nearing commercialization. Truist Securities initiated a Buy rating with a $140 price target, and Jefferies raised its price target to $164, both impressed by the drugs' performance and potential market share. The company recently completed a public offering, raising approximately $500 million to further support its biopharmaceutical advancements.
Nuvalent (Nasdaq: NUVL) to Raise $500M in Common Stock Offering, 15% Option
Nuvalent (Nasdaq: NUVL) announced an underwritten public offering of Class A common stock aiming to raise $500 million. The offering includes a 30-day option for underwriters to purchase an additional 15% of shares from selling stockholders, from which Nuvalent will not receive proceeds. J.P. Morgan, Jefferies, TD Cowen, and Cantor are serving as joint book-running managers, and the offering is made under an effective shelf registration statement.
Nuvalent (Nasdaq: NUVL) prices $500M public stock offering at $101 per share
Nuvalent, Inc. (Nasdaq: NUVL) announced the pricing of an underwritten public offering of 4,950,496 shares of Class A common stock at $101.00 per share, aiming to raise approximately $500.0 million in gross proceeds. The offering is expected to close on November 20, 2025. Additionally, selling stockholders have granted underwriters a 30-day option to purchase up to 742,574 additional shares, though Nuvalent will not receive proceeds from these sales.
Nuvalent Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares from Selling Stockholders
Nuvalent, Inc. announced the closing of its underwritten public offering of 4,950,496 shares of Class A common stock at $101.00 per share, generating approximately $500.0 million in gross proceeds. Additionally, the underwriters fully exercised their option to purchase an additional 742,574 shares from selling stockholders. This offering, managed by J.P. Morgan, Jefferies, TD Cowen, and Cantor, was made pursuant to an automatically effective shelf registration statement.
Nuvalent Director and 10% Owner Matthew Shair Sells 7,500 Shares
Matthew Shair, a Director and 10% Owner of Nuvalent, sold 7,500 shares of Class A Common Stock for $820,273 on November 24, 2025, through a Rule 10b5-1 trading plan. The transactions occurred at prices between $107.7 and $110.42. Following the sale, Shair directly holds 1,377,194 shares and indirectly owns an additional 201,672 shares through a family trust.
Nuvalent Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares from Selling Stockholders
Nuvalent, Inc. announced the closing of its underwritten public offering of 4,950,496 shares of Class A common stock at $101.00 per share, generating gross proceeds of approximately $500.0 million for the company. Additionally, the underwriters fully exercised their option to purchase an additional 742,574 shares from selling stockholders, with Nuvalent receiving no proceeds from this portion of the sale. J.P. Morgan, Jefferies, TD Cowen, and Cantor acted as joint book-running managers for the offering.
